BACKGROUND: Candidate genes associated with cardiovascular disease (CVD) represent potential risk factors for the metabolic syndrome (MetS). METHODS: The association between prevalent MetS and a panel of 62 polymorphisms within 42 candidate genes, previously implicated in the pathophysiology of CVD, were investigated in 20,806 white participants of the Women's Health Study. All were free of known CVD and diabetes at baseline. Logistic regression was performed to investigate the relationship between genotype and the MetS assuming an additive model. Stratified analyses by hormone therapy use were also performed. Correction for multiple testing was performed using false discovery rate for polymorphisms and false positive rate probability for stratified analysis, respectively. RESULTS: The prevalence of the MetS was 23%. In a marker-by-marker analysis, the ADRB2 rs180088 (OR 1.22, 95% CI 1.01-1.48) and PAI1 rs1799768 (OR 1.05, 95% CI 1.01-1.10) were associated with an increased MetS risk, whereas the C5 rs17611 (OR 0.95, 95% CI 0.91-1.00) and the CTLA4 rs5742909 (OR 0.91, 95% CI 0.84-0.99) were associated with a decreased risk. In postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk. However, none remained significant after false discovery rate correction. In a stratified analysis, one or more copies of the variant C allele of SCNN1A rs5742912 were associated with an increased MetS risk among the current users (OR 1.56, 95% CI 1.21-2.01, P interaction .007, false positive rate probability 0.13). CONCLUSIONS: Effect modification of the SCNN1A rs5742912 on the MetS by hormone therapy use warrants further investigation.
RCT Entities:
BACKGROUND: Candidate genes associated with cardiovascular disease (CVD) represent potential risk factors for the metabolic syndrome (MetS). METHODS: The association between prevalent MetS and a panel of 62 polymorphisms within 42 candidate genes, previously implicated in the pathophysiology of CVD, were investigated in 20,806 white participants of the Women's Health Study. All were free of known CVD and diabetes at baseline. Logistic regression was performed to investigate the relationship between genotype and the MetS assuming an additive model. Stratified analyses by hormone therapy use were also performed. Correction for multiple testing was performed using false discovery rate for polymorphisms and false positive rate probability for stratified analysis, respectively. RESULTS: The prevalence of the MetS was 23%. In a marker-by-marker analysis, the ADRB2rs180088 (OR 1.22, 95% CI 1.01-1.48) and PAI1rs1799768 (OR 1.05, 95% CI 1.01-1.10) were associated with an increased MetS risk, whereas the C5 rs17611 (OR 0.95, 95% CI 0.91-1.00) and the CTLA4rs5742909 (OR 0.91, 95% CI 0.84-0.99) were associated with a decreased risk. In postmenopausal women, an increased MetS risk was found for the ADRB2rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1Ars5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1Ars1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk. However, none remained significant after false discovery rate correction. In a stratified analysis, one or more copies of the variant C allele of SCNN1Ars5742912 were associated with an increased MetS risk among the current users (OR 1.56, 95% CI 1.21-2.01, P interaction .007, false positive rate probability 0.13). CONCLUSIONS: Effect modification of the SCNN1Ars5742912 on the MetS by hormone therapy use warrants further investigation.
Authors: A H Kissebah; G E Sonnenberg; J Myklebust; M Goldstein; K Broman; R G James; J A Marks; G R Krakower; H J Jacob; J Weber; L Martin; J Blangero; A G Comuzzie Journal: Proc Natl Acad Sci U S A Date: 2000-12-19 Impact factor: 11.205
Authors: Larry D Atwood; Nancy L Heard-Costa; L Adrienne Cupples; Cashell E Jaquish; Peter W F Wilson; Ralph B D'Agostino Journal: Am J Hum Genet Date: 2002-09-27 Impact factor: 11.025
Authors: C Schaedel; L Marthinsen; A C Kristoffersson; R Kornfält; K O Nilsson; B Orlenius; L Holmberg Journal: J Pediatr Date: 1999-12 Impact factor: 4.406
Authors: Yong-Woo Park; Shankuan Zhu; Latha Palaniappan; Stanley Heshka; Mercedes R Carnethon; Steven B Heymsfield Journal: Arch Intern Med Date: 2003-02-24
Authors: Maple M Fung; Fangwen Rao; Sameer Poddar; Manjula Mahata; Srikrishna Khandrika; Sushil K Mahata; Daniel T O'Connor Journal: Am J Hypertens Date: 2010-09-23 Impact factor: 2.689
Authors: Eusebio Chiefari; Sinan Tanyolaç; Stefania Iiritano; Angela Sciacqua; Carmelo Capula; Biagio Arcidiacono; Aurora Nocera; Katiuscia Possidente; Francesco Baudi; Valeria Ventura; Giuseppe Brunetti; Francesco S Brunetti; Raffaella Vero; Raffaele Maio; Manfredi Greco; Maria Pavia; Ugur Hodoglugil; Vincent Durlach; Clive R Pullinger; Ira D Goldfine; Francesco Perticone; Daniela Foti; Antonio Brunetti Journal: Sci Rep Date: 2013 Impact factor: 4.379